Unlocking the Dormant Pool: Hippo and mTOR Signaling Cascades
The mammalian ovary maintains a finite reserve of primordial follicles, the vast majority of which remain quiescent. Groundbreaking work over the past decade has elucidated the biochemical switches governing this dormancy. Mechanical fragmentation of ovarian cortical tissue disrupts the Hippo signaling pathway, converting globular actin to filamentous actin and upregulating CCN growth factors to awaken dormant follicles, a mechanism demonstrated in early cohorts of approximately 27 to 37 patients.
Concurrently, intracellular networks such as the PI3K/Akt/mTOR and FOXO3a pathways act as critical regulatory gates. While disruptions or loss-of-function mutations in inhibitory molecules like PTEN, Foxo3a, and Foxl2 lead to premature exhaustion of the reserve, pharmacological agents like everolimus or urolithin A can suppress mTOR signaling to protect and preserve the dormant pool during xenotransplantation or cytotoxic exposures.
Evaluating In Vitro Activation (IVA) and Regenerative Adjuncts
In Vitro Activation (IVA), combined with autologous tissue transplantation, has emerged as a novel experimental avenue for patients facing primary ovarian insufficiency. Prospective studies involving small groups of infertile women demonstrated that tissue vitrification, fragmentation, and pharmacological treatment can promote follicle growth, leading in some cases to oocyte retrieval and live births. However, alternative studies highlight that combining tissue vitrification with Akt stimulators fails to consistently improve follicular density in xenograft models.
Furthermore, regenerative approaches utilizing mesenchymal stem cell-derived extracellular vesicles (MSC-Exos) show promise in preclinical models by targeting apoptosis, autophagy, and oxidative stress to restore estrous cyclicity and reduce FSH levels. Despite these encouraging mechanistic findings, these treatments remain classified as experimental or trial-only, demanding rigorous clinical validation before entering routine guideline-based care.